On May 7, 2025, renowned analyst Richard Law from Goldman Sachs issued an update regarding Viridian Therapeutics (VRDN, Financial). Goldman Sachs has maintained its "Buy" rating on VRDN, signaling continued confidence in the stock despite recent adjustments.
The price target for Viridian Therapeutics (VRDN, Financial) has been lowered from its prior target of $31.00 to a new target of $27.00 USD. This adjustment represents a decrease of approximately 12.90%. The updated price target reflects current market conditions and expectations for the company's financial performance.
Viridian Therapeutics (VRDN, Financial) continues to be a focal point for investors, as Goldman Sachs' maintained rating suggests potential for future growth despite the lowered price target. Investors are advised to keep an eye on any further updates and market movements.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 16 analysts, the average target price for Viridian Therapeutics Inc (VRDN, Financial) is $39.69 with a high estimate of $61.00 and a low estimate of $19.00. The average target implies an upside of 222.07% from the current price of $12.32. More detailed estimate data can be found on the Viridian Therapeutics Inc (VRDN) Forecast page.
Based on the consensus recommendation from 17 brokerage firms, Viridian Therapeutics Inc's (VRDN, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Viridian Therapeutics Inc (VRDN, Financial) in one year is $109.34, suggesting a upside of 787.32% from the current price of $12.3225. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Viridian Therapeutics Inc (VRDN) Summary page.
